Vertex provides updates on multiple kidney programs at the american society of nephrology (asn) annual kidney week congress

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today provided updates on multiple kidney diseases in its pipeline including iga nephropathy (igan), primary membranous nephropathy (pmn), and apol1-mediated kidney disease (amkd). these updates demonstrate the transformative potential of vertex's investigational therapies in multiple serious kidney diseases, and include positive new data on povetacicept, a dual inhibitor of the baff and april pathways, in igan and pmn,.
VRTX Ratings Summary
VRTX Quant Ranking